BNA’s Health Care Daily Report™ sets the standard for reliable, high-intensity coverage of breaking health care news, covering all major legal, policy, industry, and consumer developments in a...
May 24 — The latest HHS regulatory agenda gives the Medicare agency a few years to work on a controversial rule on Medicare payments for drugs administered in a physician's office, but the agency and stakeholders say there are no plans to delay the final rule.
“We have not announced a change in timing and we continue to review comments,” Aaron Albright, director of the Media Relations Group at the Centers for Medicare & Medicaid Services, told Bloomberg BNA May 24.
The agenda notice said that final action for the Part B Drug Payment Model (CMS-1670-F; RIN:0938-AS85) would be in March 2019, three years after the proposal was published. The comment period closed May 9.
On May 18, the federal government posted its spring regulatory agenda online at reginfo.gov.
The model, a two-phase test comparing reimbursement levels and value-based purchasing options, has been sharply criticized, for the most part, by members of Congress and the medical community.
The first phase would involve changing the current methods of reimbursing claims, at the average sales price plus 6 percent, to reimbursement at ASP plus 2.5 percent with a flat fee of $16.80. The second phase would add on value-based purchasing strategies, such as indication-based pricing, reference pricing and clinical decision support tools, to reduce costs for Part B drugs.
Among the criticisms are that it would diminish Medicare providers’ ability to obtain Part B therapies, and in turn, threaten patient access to needed medicines. Some say practices would be unable to keep operating.
In addition, test and control groups would randomize patients based on where they are treated, yet there would be no “informed consent” and patients could not opt out.
When the proposed rule was issued, the CMS said plans are for the first phase of the proposal, designed to test different physician and patient incentives to encourage prescribing the most effective drugs, to be implemented in the second half of 2016. The second phase of the five-year model would be introduced early in 2017 (46 HCDR, 3/9/16).
The notation of “final action” on the regulation notice was indicative of the statutory deadline for issuance of a final rule, not the expected time for finalization, Albright said.
Elizabeth Carpenter, a senior vice president at Avalere Health, a consulting company, said that despite the opposition, she believes that the administration will move forward on the model this year, particularly because of the significant focus on high drug prices.
The high cost of infusion and other Part B drugs has raised concerns for years.
Ted Okon, executive director of the Community Oncology Alliance, told Bloomberg BNA May 24 that, although his group wants the proposal withdrawn, he has no reason to believe that the agency's proposed timeline has changed.
The 2019 date in the notice is merely a regulatory procedural matter, he said.
The rule has been the subject of hundreds of comments, mostly negative, and a House subcommittee hearing (96 HCDR, 5/18/16).
Okon said that the Obama administration likely wants to see the rule finalized before the president leaves office. In such a case, the first phase would have to be finalized by the summer to have implementation in the fall.
Depending on the final publication, the Okon's alliance will consider legal action based on the belief that the CMS exceeded its authority to make changes that would result in beneficiaries receiving a diminished benefit, he said.
To contact the reporter on this story: Mindy Yochelson in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Kendra Casey Plank at email@example.com
The spring 2016 regulatory agenda for Department of Health and Human Services rules is at http://src.bna.com/fiF.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)